SBIR Phase II: A New Biotherapeutic Approach to Combating Unwanted Bacteria

Information

• NSF Award
• 0421991

Owner

• ConjuGon, Inc.

• Award Id

  0421991

• Award Effective Date

  7/15/2004 - 20 years ago

• Award Expiration Date

  6/30/2006 - 18 years ago

• Award Amount

  $ 498,903.00

• Award Instrument

  Standard Grant

0421991<br/>Suzuki<br/><br/>This Small Business Innovation Research Phase II research project will develop a commercial biotherapeutic using a unique bacterial conjugation technology to deliver cytotoxic genes and their products to bacterial pathogens. The Phase I work successfully demonstrated proof of concept by effectively killing multi drug resistant bacteria in vitro. The Phase II project will optimize the technology further to create a treatment for nosocomial (hospital acquired) urinary tract infections. <br/><br/>The commercial application of this project will be in the area of anti-infective therapy. The proposed work provides a unique therapeutic approach that can compliment standard antibiotic therapies as well as reduce the dire problem of the burgeoning development of antibiotic-resistant bacteria in the clinic.

• Program Officer

  F.C. Thomas Allnutt

• Min Amd Letter Date

  7/12/2004 - 20 years ago

• Max Amd Letter Date

  7/12/2004 - 20 years ago

• ARRA Amount

• Name

  CONJUGON

• City

  MADISON

• State

  WI

• Country

  United States

• Address

  505 S ROSA RD STE 29

• Postal Code

  537196006

• Phone Number

  6084412890

• First Name

  Hideki

• Last Name

  Suzuki

• Email Address

  hsuzuki@conjugon.com

• Start Date

  7/12/2004 12:00:00 AM

• Name

  Agriculture

• Code

  201000